AIMD Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions has a net margin of -15991.17% compared to Ainos's net margin of -307.88%. Ainos's return on equity of -52.95% beat Intelligent Bio Solutions's return on equity of -176.44%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 751.06%. Given that Intelligent Bio Solutions has higher upside potential than Ainos, analysts believe Intelligent Bio Solutions is more attractive than Ainos.

Ainos has a beta of 1.415, which suggesting that the stock is 41.502% more volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than Intelligent Bio Solutions quarterly revenues of $872.3K. Ainos's net income of -$3.7M is lower than Intelligent Bio Solutions's net income of -$2.7M. Notably, Ainos's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 42.64x versus 0.66x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -15991.17% compared to Ainos's net margin of -59.9%. Ainos's return on equity of -52.95% beat Standard BioTools's return on equity of -48.03%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Standard BioTools has an analysts' consensus of $3.08 which suggests that it could grow by 76.19%. Given that Standard BioTools has higher upside potential than Ainos, analysts believe Standard BioTools is more attractive than Ainos.

Ainos has a beta of 1.415, which suggesting that the stock is 41.502% more volatile than S&P 500. In comparison Standard BioTools has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.231%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than Standard BioTools quarterly revenues of $45M. Ainos's net income of -$3.7M is higher than Standard BioTools's net income of -$26.9M. Notably, Ainos's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 42.64x versus 3.14x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -15991.17% compared to Ainos's net margin of -11.09%. Ainos's return on equity of -52.95% beat LENSAR's return on equity of -56.16%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand LENSAR has an analysts' consensus of $11.00 which suggests that it could grow by 31.74%. Given that LENSAR has higher upside potential than Ainos, analysts believe LENSAR is more attractive than Ainos.

Ainos has a beta of 1.415, which suggesting that the stock is 41.502% more volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than LENSAR quarterly revenues of $13.5M. Ainos's net income of -$3.7M is lower than LENSAR's net income of -$1.5M. Notably, Ainos's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 42.64x versus 1.95x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of -15991.17% compared to Ainos's net margin of -95.71%. Ainos's return on equity of -52.95% beat Zomedica's return on equity of -27.17%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 80.9%. Given that Zomedica has higher upside potential than Ainos, analysts believe Zomedica is more attractive than Ainos.

Ainos has a beta of 1.415, which suggesting that the stock is 41.502% more volatile than S&P 500. In comparison Zomedica has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.877%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $20.7K, which are smaller than Zomedica quarterly revenues of $7M. Ainos's net income of -$3.7M is higher than Zomedica's net income of -$6.7M. Notably, Ainos's price-to-earnings ratio is -- while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 42.64x versus 5.07x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.